Literature DB >> 9541479

Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients.

H Ida1, O M Rennert, T Ito, K Maekawa, Y Eto.   

Abstract

Gaucher disease is caused by a deficiency of glucocerebrosidase, resulting in hepatosplenomegaly, pancytopenia, growth retardation and skeletal involvement. We analyzed data on genotype and key clinical parameters in 35 Japanese patients with Gaucher disease type 1. Our data demonstrated that over 60% of patients had onset of Gaucher disease signs/symptoms at less than 5 years. Sixty percent and 46% of evaluable patients were splenectomized and developed severe bone involvement, respectively. Within mean follow-up periods of 8 years and 4 months, mean relative height and weight, severity score index and platelet count all worsened to a highly significant degree. These data suggest that type 1 Gaucher disease tends to be severe and progressive in Japanese patients, most of whom would be suitable for treatment and might indeed require earlier and more aggressive therapy.

Entities:  

Mesh:

Year:  1998        PMID: 9541479     DOI: 10.1006/bcmd.1998.0172

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  11 in total

1.  The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations.

Authors:  P Maaswinkel-Mooij; C Hollak; M van Eysden-Plaisier; M Prins; H Aerts; R Pöll
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

2.  Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.

Authors:  Juliette Berger; Marie Vigan; Bruno Pereira; Thu Thuy Nguyen; Roseline Froissart; Nadia Belmatoug; Florence Dalbiès; Agathe Masseau; Christian Rose; Christine Serratrice; Yves-Marie Pers; Ivan Bertchansky; Fabrice Camou; Monia Bengherbia; Céline Bourgne; Catherine Caillaud; Magali Pettazzoni; Amina Berrahal; Jérôme Stirnemann; France Mentré; Marc G Berger
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

3.  Successful treatment of Gaucher disease type 1 by enzyme replacement therapy over a 10-year duration in a Japanese pediatric patient: A case report.

Authors:  Yuji Oto; Takeshi Inoue; So Nagai; Shinichiro Tanaka; Hisashi Itabashi; Masahisa Shiraisihi; Akihisa Nitta; Nobuyuki Murakami; Hiroyuki Ida; Tomoyo Matsubara
Journal:  Exp Ther Med       Date:  2021-01-22       Impact factor: 2.447

4.  Severe skeletal complications in Japanese patients with type 1 Gaucher disease.

Authors:  H Ida; O M Rennert; S Kato; T Ueda; K Oishi; K Maekawa; Y Eto
Journal:  J Inherit Metab Dis       Date:  1999-02       Impact factor: 4.982

5.  Improvement of splenomegaly and pancytopenia by enzyme replacement therapy against type 1 Gaucher disease: a report of sibling cases.

Authors:  K Tsuboi; S Iida; M Kato; Y Hayami; I Hanamura; K Miura; S Harada; H Komatsu; S Banno; A Wakita; M Nitta; R Ueda
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

6.  Clinical and molecular characteristics of Japanese Gaucher disease.

Authors:  Y Eto; H Ida
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

7.  Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.

Authors:  P Grigorescu Sido; C Drugan; V Cret; C Al-Kzouz; C Denes; C Coldea; A Zimmermann
Journal:  J Inherit Metab Dis       Date:  2007-08-20       Impact factor: 4.982

Review 8.  Ethical issues in managing Lysosomal storage disorders in children in low and middle income countries.

Authors:  Bushra Afroze; Nick Brown
Journal:  Pak J Med Sci       Date:  2017 Jul-Aug       Impact factor: 1.088

9.  Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review.

Authors:  Divair Doneda; Cristina B Netto; Cileide C Moulin; Ida Vanessa D Schwartz
Journal:  Nutr Metab (Lond)       Date:  2013-04-09       Impact factor: 4.169

Review 10.  Missing Cells: Pathophysiology, Diagnosis, and Management of (Pan)Cytopenia in Childhood.

Authors:  Miriam Erlacher; Brigitte Strahm
Journal:  Front Pediatr       Date:  2015-07-13       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.